Clinical Trials Browser

Phase 4 × lorlatinib × Tumor-Agnostic × Clear all

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Carcinoma